Launonen, I.-M. http://orcid.org/0000-0002-4548-9650
Lyytikäinen, N.
Casado, J. http://orcid.org/0000-0002-3662-8794
Anttila, E. A. http://orcid.org/0000-0001-8526-4934
Szabó, A.
Haltia, U.-M.
Jacobson, C. A. http://orcid.org/0000-0002-0299-3451
Lin, J. R.
Maliga, Z.
Howitt, B. E.
Strickland, K. C.
Santagata, S. http://orcid.org/0000-0002-7528-9668
Elias, K.
D’Andrea, A. D. http://orcid.org/0000-0001-6168-6294
Konstantinopoulos, P. A. http://orcid.org/0000-0002-1032-1479
Sorger, P. K. http://orcid.org/0000-0002-3364-1838
Färkkilä, A. http://orcid.org/0000-0002-3558-6617
Funding for this research was provided by:
Suomen Lääketieteen Säätiö
Instrumentariumin Tiedesäätiö
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U54-CA225088)
Article History
Received: 30 September 2021
Accepted: 14 January 2022
First Online: 11 February 2022
Competing interests
: P.K.S. is a member of the SAB or Board of Directors of Applied Bio-math, Glencoe Software, RareCyte Inc., and has equities in these companies; he is a member of the SAB of NanoString Inc. and a consultant for Merck and Montai Health. P.K.S. has received research funding from Novartis and Merck. None of the above declared relationships has influenced the content of this manuscript. The other authors report no conflicts of interest.